BGMS

#4899
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.86
0.86
Intervallo Annuale
0.57
6.70
Variazione giornaliera
-3.37%
Variazione Mensile
-1.15%
Variazione di 6 mesi
-10.06%
Variazione Annuale
-85.67%
Chiusura Precedente
0.8 9
Open
0.8 6
Minimo
0.8 6
Massimo
0.8 6
Volume
3
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q2 FY2006

Full document

Business Context and Reporting Period

This Form 8-K was filed by Cyclacel Pharmaceuticals, Inc. (formerly Bio Green Med Solution, Inc.) on April 10, 2006. The report details a change in the company's certifying accountant following a significant corporate restructuring. On March 27, 2006, the Registrant acquired all issued and outstanding share capital of Cyclacel Limited from Cyclacel Group plc in exchange for 7,761,453 shares of common stock. Concurrently, the company was renamed "Cyclacel Pharmaceuticals, Inc." and underwent a complete change in its board of directors and management.

Key Financial Metrics

The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the administrative change of the independent registered public accounting firm.

Material Changes

  • Accountant Change: Ernst & Young LLP (US) resigned as the independent registered public accounting firm on April 10, 2006. This resignation was accepted by the board of directors.
  • New Appointment: Ernst & Young LLP (UK) was appointed as the new independent registered public accounting firm to audit the Registrant's financial statements.
  • Reason for Change: The change was effected solely as a result of the completion of the Stock Purchase Agreement and the acquisition of Cyclacel Limited.

Guidance, Outlook, and Risks

The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors related to business performance. Regarding the accountant change, the Registrant confirmed that:

  • E&Y US audit reports for the years ended December 31, 2004, and 2005 did not contain adverse opinions, disclaimers, or qualifications.
  • There were no disagreements with E&Y US regarding accounting principles, practices, or auditing scope during the two most recent fiscal years.
  • No events described in Item 304(a)(1)(v) of Regulation S-K occurred during the relevant periods.
  • The Registrant did not consult E&Y UK regarding accounting principles or matters of disagreement with the former auditor prior to the appointment.

Investor Verification Checklist

  • Verify the status of the letter from E&Y US confirming agreement with the statements in this report, which the Registrant intends to file as an amendment.
  • Review the March 30, 2006 Form 8-K for detailed terms of the Stock Purchase Agreement and the acquisition of Cyclacel Limited.
  • Confirm the integration of financial reporting between the former Bio Green Med Solution, Inc. and the acquired Cyclacel Limited under the new auditor.